Biosimilar Antibodies

Trevogrumab Biosimilar – Anti-MSTN, GDF8 mAb – Research Grade, ProteoGenix, PX-TA1388

Description of Trevogrumab Biosimilar - Anti-MSTN, GDF8 mAb - Research Grade General information on Anti-MSTN/GDF8[Homo sapiens] (Trevogrumab) Monoclonal Antibody Trevogrumab has been investigated for the treatment of Orthopedic disease and Sarcopenia.

Trosovavilp alfa Biosimilar – Research Grade, ProteoGenix, PX-TA2518-100

Tulinercept Biosimilar – Anti-TNF fusion protein – Research Grade, ProteoGenix, PX-TA2023

Description of Tulinercept Biosimilar - Anti-TNF fusion protein - Research Grade Tulinercept Biosimilar: A Promising Anti-TNF Fusion Protein for Therapeutic Targeting Tulinercept Biosimilar is a novel biologic drug that has gained significant attention in the field of immunology and biotechnology. It is an anti-tumor necrosis factor (TNF) fusion protein that has shown promising results in pre-clinical studies for the treatment of various inflammatory and autoimmune diseases. In this article, we will discuss the structure, activity, and potential applications of Tulinercept Biosimilar in detail. Structure of Tulinercept Biosimilar Tulinercept Biosimilar is a recombinant fusion protein that consists of two components – a soluble TNF receptor (TNFR) and a human IgG1 Fc domain. The TNFR component is derived from the extracellular domain of human TNFR1, which is responsible for binding to TNF. The Fc domain, on the other hand, is responsible for extending the half-life of the drug and enhancing its stability. The two components are linked together by a flexible linker, resulting in a single molecule with a molecular weight of approximately 150 kDa. The structure of Tulinercept Biosimilar is similar to that of the approved biologic drug, Etanercept, which is used for the treatment of various inflammatory diseases. However, Tulinercept Biosimilar has a higher binding affinity for TNF and a longer half-life, making it a potentially more effective and convenient treatment option. Activity of Tulinercept Biosimilar The primary mechanism of action of Tulinercept Biosimilar is to bind and neutralize TNF, a pro-inflammatory cytokine that plays a crucial role in the pathogenesis of many autoimmune and inflammatory diseases. TNF is known to induce the production of other inflammatory cytokines, activate immune cells, and promote tissue damage, making it a prime therapeutic target for these conditions. Tulinercept Biosimilar works by binding to TNF and preventing it from interacting with its receptors on immune cells. This leads to a decrease in the production of inflammatory cytokines and a reduction in immune cell activation, ultimately resulting in a decrease in disease symptoms and progression. Potential Applications of Tulinercept Biosimilar Tulinercept Biosimilar has shown promising results in pre-clinical studies for the treatment of various inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, Crohn’s disease, and ulcerative colitis. It has also been studied for its potential in treating other conditions such as ankylosing spondylitis, juvenile idiopathic arthritis, and psoriatic arthritis. In addition to its potential as a therapeutic drug, Tulinercept Biosimilar also has potential applications in research and diagnostic settings. Its high binding affinity for TNF makes it a valuable tool for studying the role of TNF in various diseases and for developing diagnostic assays to measure TNF levels in patient samples. Conclusion Tulinercept Biosimilar is a promising anti-TNF fusion protein with a unique structure and mechanism of action. It has the potential to be a more effective and convenient treatment option for various inflammatory and autoimmune diseases, and its applications in research and diagnostics make it a versatile and valuable drug. Further clinical studies are needed to fully understand its safety and efficacy, but the early results are promising, and Tulinercept Biosimilar has the potential to make a significant impact in the field of immunology and biotechnology.

Tusamitamab Biosimilar – Anti-CEACAM5 mAb – Research Grade, ProteoGenix, PX-TA1729

Description of Tusamitamab Biosimilar - Anti-CEACAM5 mAb - Research Grade Introduction to Tusamitamab Biosimilar – A Revolutionary Anti-CEACAM5 mAb Tusamitamab Biosimilar, also known as Anti-CEACAM5 mAb, is a novel monoclonal antibody (mAb) that has gained significant attention in the field of cancer research. This innovative antibody is designed to target the carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), a protein that is overexpressed in various types of cancer cells. In this article, we will delve into the structure, activity, and potential applications of Tusamitamab Biosimilar, highlighting its potential as a therapeutic option for cancer treatment. Structure of Tusamitamab Biosimilar Tusamitamab Biosimilar is a recombinant, humanized IgG1 monoclonal antibody that is produced using advanced biotechnology techniques. It is composed of two heavy chains and two light chains, each of which contains a variable region that specifically binds to CEACAM5. The constant region of the antibody is responsible for its effector functions, such as antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Activity of Tusamitamab Biosimilar The primary mechanism of action of Tusamitamab Biosimilar is its ability to bind to CEACAM5, a glycoprotein that is highly expressed on the surface of cancer cells. This binding leads to the inhibition of CEACAM5-mediated cell signaling pathways, which are involved in tumor growth, invasion, and metastasis. In addition, Tusamitamab Biosimilar can also induce antibody-dependent cellular cytotoxicity, where immune cells recognize and destroy cancer cells that are marked with Tusamitamab Biosimilar. Potential Applications of Tusamitamab Biosimilar Tusamitamab Biosimilar has shown promising results in preclinical and clinical studies as a potential therapeutic option for various types of cancer. Its high specificity for CEACAM5 makes it a promising candidate for the treatment of colorectal, lung, and pancreatic cancers, which are known to overexpress this protein. In addition, Tusamitamab Biosimilar has also shown potential in treating triple-negative breast cancer, a highly aggressive and difficult-to-treat form of breast cancer. Recent clinical trials have demonstrated the efficacy of Tusamitamab Biosimilar in combination with chemotherapy in the treatment of advanced colorectal cancer. In a phase II study, this combination therapy showed a significant improvement in overall survival and progression-free survival compared to chemotherapy alone. Furthermore, Tusamitamab Biosimilar has also shown promising results in combination with other targeted therapies, such as anti-EGFR agents, in the treatment of colorectal cancer. Apart from its potential as a therapeutic option, Tusamitamab Biosimilar is also being explored for its diagnostic and prognostic value. CEACAM5 is not only overexpressed in cancer cells but also shed into the blood, making it a potential biomarker for cancer detection and monitoring. Tusamitamab Biosimilar, being a specific binder of CEACAM5, can be used in diagnostic tests to detect the presence of this protein in blood samples. Conclusion Tusamitamab Biosimilar, also known as Anti-CEACAM5 mAb, is a highly promising monoclonal antibody that targets the overexpressed protein CEACAM5 in various types of cancer. Its unique structure and mechanism of action make it a potential therapeutic option for the treatment of colorectal, lung, and pancreatic cancers, as well as triple-negative breast cancer. Furthermore, Tusamitamab Biosimilar also has potential diagnostic and prognostic applications, highlighting its versatility and potential impact in the field of cancer research. Further research and clinical trials are needed to fully explore the potential of this revolutionary antibody in the fight against cancer.

Uliledlimab Biosimilar – Anti-NT5E mAb – Research Grade, ProteoGenix, PX-TA1730

Description of Uliledlimab Biosimilar - Anti-NT5E mAb - Research Grade Introduction Uliledlimab Biosimilar, also known as Anti-NT5E mAb, is a monoclonal antibody that targets the enzyme CD73, also known as NT5E. This enzyme is involved in the production of adenosine, a molecule that plays a key role in regulating the immune response. By inhibiting CD73, Uliledlimab Biosimilar has the potential to modulate the immune system and treat various diseases. In this article, we will explore the structure, activity, and potential applications of Uliledlimab Biosimilar as a research grade antibody. Structure of Uliledlimab Biosimilar Uliledlimab Biosimilar is a fully human monoclonal antibody, meaning it is derived from human cells and has a high level of specificity and affinity for its target. It is composed of two identical heavy chains and two identical light chains, each containing a variable region that binds specifically to CD73. The structure of Uliledlimab Biosimilar is similar to that of other therapeutic antibodies, with a Y-shaped structure and a flexible hinge region that allows for binding to multiple targets. Activity of Uliledlimab Biosimilar The main activity of Uliledlimab Biosimilar is its ability to inhibit the activity of CD73. This enzyme is expressed on the surface of various immune cells, including T cells, B cells, and natural killer cells. CD73 is responsible for converting extracellular ATP to adenosine, which has immunosuppressive effects. By inhibiting CD73, Uliledlimab Biosimilar can prevent the production of adenosine and potentially enhance the immune response. Additionally, Uliledlimab Biosimilar has been shown to have anti-inflammatory effects by reducing the production of pro-inflammatory cytokines and chemokines. This activity has been demonstrated in various pre-clinical studies, making Uliledlimab Biosimilar a promising candidate for the treatment of inflammatory diseases. Potential Applications of Uliledlimab Biosimilar As a research grade antibody, Uliledlimab Biosimilar has the potential to be used in a variety of studies and experiments. Its main application is in the field of immunology, where it can be used to investigate the role of CD73 in the immune response and its potential as a therapeutic target. Uliledlimab Biosimilar may also have potential applications in the treatment of various diseases. Its ability to modulate the immune response could make it a valuable tool in the treatment of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Additionally, its anti-inflammatory effects could be beneficial in the treatment of inflammatory conditions, such as asthma and inflammatory bowel disease. Furthermore, Uliledlimab Biosimilar has shown promising results in pre-clinical studies for the treatment of cancer. By inhibiting CD73, it can prevent the production of adenosine, which is known to suppress the immune response against tumors. This makes Uliledlimab Biosimilar a potential candidate for combination therapy with other cancer treatments. Conclusion In summary, Uliledlimab Biosimilar is a monoclonal antibody that targets CD73 and has the potential to modulate the immune response and treat various diseases. Its structure, activity, and potential applications make it a valuable tool for research and a promising candidate for therapeutic use. Further studies and clinical trials are needed to fully understand the potential of Uliledlimab Biosimilar as a therapeutic antibody.

Ulocuplumab Biosimilar – Anti-CXCR4, CD184 mAb – Research Grade, ProteoGenix, PX-TA1339

Description of Ulocuplumab Biosimilar - Anti-CXCR4, CD184 mAb - Research Grade General information on Anti-CXCR4/CD184[Homo sapiens] (Ulocuplumab) Monoclonal Antibody Ulocuplumab is investigated for the treatment of Solid Tumors.

Urelumab Biosimilar – Anti-TNFRSF9, CD137 mAb – Research Grade, ProteoGenix, PX-TA1265

Description of Urelumab Biosimilar - Anti-TNFRSF9, CD137 mAb - Research Grade General information on Anti-TNFRSF9/CD137 [Homo sapiens] (Urelumab) Monoclonal Antibody Urelumab is a human antibody targeting CD137. Urelumab has been investigated for the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, Cancer – Solid Tumors and B-Cell Non-Hodgkin’s Lymphoma.

Ustekinumab Biosimilar – Anti-Human IL-12 IL-23 mAb – Research Grade, ProteoGenix, PX-TA1011

Description of Ustekinumab Biosimilar - Anti-Human IL-12 IL-23 mAb - Research Grade General information about Ustekinumab Ustekinumab is a human monoclonal antibody used to treat psoriasis. It is also approved to treat Crohn’s disease and ulcerative colitis among people who have not responded to more traditional treatments. It is a subcutaneous human interleukin 12 and interleukin 23 antagonist. These are naturally occurring proteins that regulate the immune system and immune-mediated inflammatory disorders. This product is for research use only.

Utomilumab Biosimilar – Anti-Human TNFRSF9 mAb – Research Grade, ProteoGenix, PX-TA1012

Description of Utomilumab Biosimilar - Anti-Human TNFRSF9 mAb - Research Grade General information about Utomilumab Utomilumab is a monoclonal antibody that binds to 4-IBB protein (also known as CD137 protein). 4-IBB protein is a receptor found in different immune cells such as helper T-cells, killer T-cells and natural killer cells. 4-IBB/CD137 protein is a costimulatory receptor whose activation results in a series of events that leads to cytokine secretion and effector functions. Hence, targeting CD137 protein has been linked to antitumor immunity response and overall tumor reduction. Indeed, once utomilumab is injected in the bloodstream its specific binding to CD137 protein stimulates the immune cells which, as a result, enhances the immune response against tumors. Utomilumab is under investigation as a potential treatment for advanced forms of cancer either alone or in combination with other therapies. Indeed, pre-clinical studies have suggested that the combination of utomilumab with a checkpoint inhibitor such as anti-PD1/anti-PDL1, or other immunotherapies may lead to amplified immune response. This demonstrates utomilumab anti-tumor activity. Phase 1 study evaluated the outcome of administering utomilumab in combination with rituximab in patients with certain type of non-Hodgkin’s lymphoma (NHL) also known as CD20-positive NHL. Phase I clinical trial results further confirmed the anti-tumor activity of utomilumab. The utomilumab administration with rituximab was well tolerated and none of the patients interrupted the treatment because of treatment-related side effects. No dose-related toxicities were recorded. The safety and anti-tumor activity of this antibody-based therapy was assessed in phase 1b clinical trial. Utomilumab was tested in combination with pembrolizumab for different advanced solid tumors including renal cell carcinoma, head and neck cancer, thyroid cancer, pancreatic cancer, non-small cell lung cancer, small cell lung cancer, colon cancer, sarcoma, thymoma and melanoma. Result showed that the administration of utomilumab together with pembrolizumab to patients with solid tumors was safe. Once again, no toxicity was observed with increased doses of utomilumab. This product is for research use only.

Vandortuzumab Biosimilar – Anti-STEAP1 mAb – Research Grade, ProteoGenix, PX-TA1370

Description of Vandortuzumab Biosimilar - Anti-STEAP1 mAb - Research Grade Introduction to Vandortuzumab Biosimilar Vandortuzumab Biosimilar, also known as Anti-STEAP1 mAb, is a monoclonal antibody that specifically targets the STEAP1 protein. This biosimilar is a research grade antibody that has been developed as a potential therapeutic agent for various diseases. Structure of Vandortuzumab Biosimilar Vandortuzumab Biosimilar is a recombinant humanized monoclonal antibody that has been designed to mimic the structure and function of the naturally occurring antibody. It is composed of two heavy chains and two light chains, each containing variable and constant regions. The variable regions of the antibody are responsible for binding to the STEAP1 protein, while the constant regions play a role in immune system activation. Activity of Vandortuzumab Biosimilar The main activity of Vandortuzumab Biosimilar is to bind to the STEAP1 protein, which is overexpressed in various types of cancer cells. This binding leads to the inhibition of STEAP1 function, which is involved in cell proliferation, migration, and invasion. By targeting STEAP1, Vandortuzumab Biosimilar can potentially block the growth and spread of cancer cells. In addition to its anti- cancer activity, Vandortuzumab Biosimilar also has immunomodulatory effects. It can activate the immune system to recognize and attack cancer cells, leading to a more robust and effective anti-tumor response. Application of Vandortuzumab Biosimilar Vandortuzumab Biosimilar has been investigated as a potential therapeutic agent for various types of cancer, including prostate, breast, and bladder cancer. It has shown promising results in preclinical studies, demonstrating its ability to inhibit tumor growth and improve survival rates. In addition to its potential as a cancer treatment, Vandortuzumab Biosimilar has also been studied as a diagnostic tool. Its ability to specifically target STEAP1 makes it a valuable tool for detecting the presence of STEAP1 in cancer cells, which can aid in the diagnosis and monitoring of cancer. Conclusion In summary, Vandortuzumab Biosimilar is a research grade monoclonal antibody that specifically targets the STEAP1 protein. Its structure and activity make it a promising therapeutic agent for various types of cancer, with potential applications in both treatment and diagnosis. Further research and clinical trials are needed to fully evaluate the efficacy and safety of Vandortuzumab Biosimilar, but it holds great potential as a novel anti- cancer therapy.